Liu X, Rapp N, Deans R, Cheng L
Osiris Therapeutics, Inc., Baltimore, Maryland 21231, USA.
Genomics. 2000 May 1;65(3):283-92. doi: 10.1006/geno.2000.6170.
A rare population of human bone marrow (BM) and cord blood (CB) mononuclear cells bearing the CD34 surface marker (CD34+) function as hematopoietic stem/progenitor cells. Cells lacking CD34 expression (CD34-) in BM and CB are largely mature hematopoietic cells of various lineages that are derived from the CD34+ cells. To elucidate molecular mechanisms governing functional differences between CD34+ and CD34- hematopoietic cells, we used representational difference analysis (RDA)-based subtraction to identify genes that are specifically or preferentially expressed in CD34+ cells. Among the 73 RDA fragments initially sequenced, 30% are derived from the CD34 and c-kit genes that are preferentially expressed in CD34+ cells. An additional 27 (37%) are novel or homologous only to entries in expressed sequence tag databases. One (C17) was found four times and is expressed in CD34+ but not in CD34- cell populations from CB or BM. The cloned C17 cDNA encodes a novel polypeptide of 136 amino acids with a signal sequence. No homology to this peptide was found in the public databases. A secondary-structure analysis predicts that the C17 peptide contains four alpha-helices, a characteristic of hematopoietic cytokines and interleukins. This novel gene is mapped to human chromosome 4p15-p16.
一小部分带有CD34表面标志物(CD34+)的人类骨髓(BM)和脐带血(CB)单核细胞具有造血干细胞/祖细胞的功能。骨髓和脐带血中缺乏CD34表达的细胞(CD34-)主要是来自CD34+细胞的各种谱系的成熟造血细胞。为了阐明调控CD34+和CD34-造血细胞功能差异的分子机制,我们使用基于代表性差异分析(RDA)的消减技术来鉴定在CD34+细胞中特异性或优先表达的基因。在最初测序的73个RDA片段中,30%来自在CD34+细胞中优先表达的CD34和c-kit基因。另外27个(37%)仅与表达序列标签数据库中的条目具有新颖性或同源性。其中一个(C17)被发现了4次,在脐带血或骨髓的CD34+细胞群体中表达,但在CD34-细胞群体中不表达。克隆的C17 cDNA编码一个具有信号序列的136个氨基酸的新型多肽。在公共数据库中未发现与该肽的同源性。二级结构分析预测C17肽包含四个α螺旋,这是造血细胞因子和白细胞介素的特征。这个新基因被定位到人类染色体4p15-p16上。